Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.

Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ.

Oncoimmunology. 2018 Feb 1;7(5):e1423172. doi: 10.1080/2162402X.2017.1423172. eCollection 2018.

PMID:
29721378
2.

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG.

J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.

PMID:
29567210
3.

The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity.

Rahman R, Cortes A, Niemierko A, Oh KS, Flaherty KT, Lawrence DP, Sullivan RJ, Shih HA.

J Neurooncol. 2018 Jun;138(2):299-306. doi: 10.1007/s11060-018-2795-7. Epub 2018 Feb 16.

PMID:
29453679
4.

Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.

Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, Toner M, Isselbacher KJ, Maheswaran S, Haber DA.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2467-2472. doi: 10.1073/pnas.1719264115. Epub 2018 Feb 16.

5.

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.

Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A.

Clin Cancer Res. 2018 Apr 15;24(8):1805-1815. doi: 10.1158/1078-0432.CCR-17-3436. Epub 2018 Jan 22.

PMID:
29358500
6.

Resistance to checkpoint blockade therapy through inactivation of antigen presentation.

Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, Frederick DT, Hazar-Rethinam M, Nadres BA, Van Seventer EE, Shukla SA, Yizhak K, Ray JP, Rosebrock D, Livitz D, Adalsteinsson V, Getz G, Duncan LM, Li B, Corcoran RB, Lawrence DP, Stemmer-Rachamimov A, Boland GM, Landau DA, Flaherty KT, Sullivan RJ, Hacohen N.

Nat Commun. 2017 Oct 26;8(1):1136. doi: 10.1038/s41467-017-01062-w.

7.

Neofusicoccum parvum Colonization of the Grapevine Woody Stem Triggers Asynchronous Host Responses at the Site of Infection and in the Leaves.

Massonnet M, Figueroa-Balderas R, Galarneau ERA, Miki S, Lawrence DP, Sun Q, Wallis CM, Baumgartner K, Cantu D.

Front Plant Sci. 2017 Jun 28;8:1117. doi: 10.3389/fpls.2017.01117. eCollection 2017.

8.

Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.

Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, Flaherty KT, Lawrence DP, Johnson DB, Sullivan RJ.

Oncologist. 2017 Aug;22(8):963-971. doi: 10.1634/theoncologist.2016-0450. Epub 2017 May 5.

9.

Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.

Friedman AA, Xia Y, Trippa L, Le LP, Igras V, Frederick DT, Wargo JA, Tanabe KK, Lawrence DP, Neuberg DS, Flaherty KT, Fisher DE.

Clin Cancer Res. 2017 Aug 15;23(16):4680-4692. doi: 10.1158/1078-0432.CCR-16-3029. Epub 2017 Apr 26.

10.

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, Margolin KA, Leitao MM Jr, Tarhini AA, Koon HB, Pecora AL, Jaslowski AJ, Cohen GI, Kuzel TM, Lao CD, Kirkwood JM.

Cancer. 2017 Jul 15;123(14):2688-2697. doi: 10.1002/cncr.30663. Epub 2017 Mar 23.

11.

Botryosphaeriaceae species associated with dieback and canker disease of bay laurel in northern California with the description of Dothiorella californica sp. nov.

Lawrence DP, Peduto Hand F, Gubler WD, Trouillas FP.

Fungal Biol. 2017 Apr;121(4):347-360. doi: 10.1016/j.funbio.2016.09.005. Epub 2016 Sep 23.

PMID:
28317539
12.

A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.

Dagogo-Jack I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, Lawrence DP, Shaw AT, Sullivan RJ.

J Immunother. 2017 Apr;40(3):108-113. doi: 10.1097/CJI.0000000000000159.

PMID:
28221189
13.

Closed-reference metatranscriptomics enables in planta profiling of putative virulence activities in the grapevine trunk disease complex.

Morales-Cruz A, Allenbeck G, Figueroa-Balderas R, Ashworth VE, Lawrence DP, Travadon R, Smith RJ, Baumgartner K, Rolshausen PE, Cantu D.

Mol Plant Pathol. 2018 Feb;19(2):490-503. doi: 10.1111/mpp.12544. Epub 2017 Mar 26.

14.

Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.

Dagi Glass LR, Lawrence DP, Jakobiec FA, Freitag SK.

Ophthalmic Plast Reconstr Surg. 2017 Sep/Oct;33(5):e114-e116. doi: 10.1097/IOP.0000000000000833.

PMID:
27893585
15.

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.

Khalil DN, Postow MA, Ibrahim N, Ludwig DL, Cosaert J, Kambhampati SR, Tang S, Grebennik D, Kauh JS, Lenz HJ, Flaherty KT, Hodi FS, Lawrence DP, Wolchok JD.

Clin Cancer Res. 2016 Nov 1;22(21):5204-5210. Epub 2016 Oct 19.

16.

Condition-dependent co-regulation of genomic clusters of virulence factors in the grapevine trunk pathogen Neofusicoccum parvum.

Massonnet M, Morales-Cruz A, Figueroa-Balderas R, Lawrence DP, Baumgartner K, Cantu D.

Mol Plant Pathol. 2018 Jan;19(1):21-34. doi: 10.1111/mpp.12491. Epub 2016 Dec 4.

17.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS.

Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270.

18.

A Symmetric Eczematous Eruption Harboring Thousands of Melanocytic Lesions.

Ratushny V, Kraft S, Moschella SL, Duncan LM, Lawrence DP, Tsao H.

JAMA Dermatol. 2016 Sep 1;152(9):1021-4. doi: 10.1001/jamadermatol.2016.1150.

PMID:
27192392
19.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.

JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. Erratum in: JAMA. 2016 Jun 14;315(22):2472.

PMID:
27092830
20.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI.

JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368.

PMID:
26633184
21.

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.

Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, Fisher DE.

PLoS One. 2015 Oct 13;10(10):e0140310. doi: 10.1371/journal.pone.0140310. eCollection 2015.

22.

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.

Buchbinder EI, Sosman JA, Lawrence DP, McDermott DF, Ramaiya NH, Van den Abbeele AD, Linette GP, Giobbie-Hurder A, Hodi FS.

Cancer. 2015 Nov 15;121(22):4007-15. doi: 10.1002/cncr.29622. Epub 2015 Aug 11.

23.

Diversity of Diaporthe species associated with wood cankers of fruit and nut crops in northern California.

Lawrence DP, Travadon R, Baumgartner K.

Mycologia. 2015 Sep-Oct;107(5):926-40. doi: 10.3852/14-353. Epub 2015 Aug 3.

PMID:
26240309
24.

Distinctive expansion of gene families associated with plant cell wall degradation, secondary metabolism, and nutrient uptake in the genomes of grapevine trunk pathogens.

Morales-Cruz A, Amrine KC, Blanco-Ulate B, Lawrence DP, Travadon R, Rolshausen PE, Baumgartner K, Cantu D.

BMC Genomics. 2015 Jun 19;16:469. doi: 10.1186/s12864-015-1624-z.

25.

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.

Sullivan RJ, Ibrahim N, Lawrence DP, Aldridge J, Giobbie-Hurder A, Hodi FS, Flaherty KT, Conley C, Mier JW, Atkins MB, McDermott DF.

Oncologist. 2015 Jun;20(6):617-8. doi: 10.1634/theoncologist.2015-0105. Epub 2015 May 18.

26.

Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.

Wattson DA, Sullivan RJ, Niemierko A, Merritt RM, Lawrence DP, Oh KS, Flaherty KT, Shih HA.

J Neurooncol. 2015 May;123(1):75-84. doi: 10.1007/s11060-015-1761-x. Epub 2015 Apr 12.

PMID:
25864098
27.

Clinical significance of microscopic melanoma metastases in the nonhottest sentinel lymph nodes.

Luo S, Lobo AZ, Tanabe KK, Muzikansky A, Durazzo T, Sober A, Tsao H, Cosimi AB, Lawrence DP, Duncan LM.

JAMA Surg. 2015 May;150(5):465-72. doi: 10.1001/jamasurg.2014.3843.

PMID:
25831227
28.

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.

Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS.

Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18.

29.

Cadophora species associated with wood-decay of grapevine in North America.

Travadon R, Lawrence DP, Rooney-Latham S, Gubler WD, Wilcox WF, Rolshausen PE, Baumgartner K.

Fungal Biol. 2015 Jan;119(1):53-66. doi: 10.1016/j.funbio.2014.11.002. Epub 2014 Nov 24.

PMID:
25601149
30.

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).

Lacouture ME, Morris JC, Lawrence DP, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Berzofsky JA, Hsu FJ, Guitart J.

Cancer Immunol Immunother. 2015 Apr;64(4):437-46. doi: 10.1007/s00262-015-1653-0. Epub 2015 Jan 13.

PMID:
25579378
31.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS.

Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.

32.

Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.

Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ.

Mol Cancer Ther. 2014 Dec;13(12):3210-8. doi: 10.1158/1535-7163.MCT-14-0349. Epub 2014 Oct 15.

33.

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R.

J Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6.

34.

Isolation and molecular characterization of circulating melanoma cells.

Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA.

Cell Rep. 2014 May 8;7(3):645-53. doi: 10.1016/j.celrep.2014.03.039. Epub 2014 Apr 18.

35.

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.

Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP.

PLoS One. 2014 Mar 11;9(3):e90353. doi: 10.1371/journal.pone.0090353. eCollection 2014.

36.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS.

J Clin Oncol. 2014 Apr 1;32(10):1020-30. doi: 10.1200/JCO.2013.53.0105. Epub 2014 Mar 3.

37.

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.

Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ.

Cancer. 2014 Jun 1;120(11):1695-701. doi: 10.1002/cncr.28620. Epub 2014 Feb 27.

38.

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA.

Cancer Discov. 2014 Jan;4(1):61-8. doi: 10.1158/2159-8290.CD-13-0631. Epub 2013 Nov 21.

39.

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes.

Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA.

Oncoimmunology. 2013 Oct 1;2(10):e26615. Epub 2013 Oct 15.

40.

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD.

Cancer. 2013 Oct 15;119(20):3687-95. doi: 10.1002/cncr.28282. Epub 2013 Aug 2.

41.

Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma.

Sullivan RJ, Lawrence DP, Wargo JA, Oh KS, Gonzalez RG, Piris A.

N Engl J Med. 2013 Jul 11;369(2):173-83. doi: 10.1056/NEJMcpc1302332. No abstract available.

PMID:
23841733
42.

Ipilimumab for patients with advanced mucosal melanoma.

Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.

Oncologist. 2013 Jun;18(6):726-32. doi: 10.1634/theoncologist.2012-0464. Epub 2013 May 28.

43.

The sections of Alternaria: formalizing species-group concepts.

Lawrence DP, Gannibal PB, Peever TL, Pryor BM.

Mycologia. 2013 May-Jun;105(3):530-46. doi: 10.3852/12-249.

PMID:
23687125
44.

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA.

Clin Cancer Res. 2013 Mar 1;19(5):1225-31. doi: 10.1158/1078-0432.CCR-12-1630. Epub 2013 Jan 10.

45.

Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.

Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D.

Clin Cancer Res. 2013 Jan 15;19(2):480-90. doi: 10.1158/1078-0432.CCR-12-1842. Epub 2012 Nov 27.

46.

Cutaneous effects of BRAF inhibitor therapy: a case series.

Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB.

Ann Oncol. 2013 Feb;24(2):530-7. doi: 10.1093/annonc/mds292. Epub 2012 Oct 3.

PMID:
23035153
47.

Origin of pisatin demethylase (PDA) in the genus Fusarium.

Milani NA, Lawrence DP, Arnold AE, VanEtten HD.

Fungal Genet Biol. 2012 Nov;49(11):933-42. doi: 10.1016/j.fgb.2012.08.007. Epub 2012 Sep 7.

PMID:
22985693
48.

Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.

Alloo A, Garibyan L, LeBoeuf N, Lin G, Werchniak A, Hodi FS Jr, Flaherty KT, Lawrence DP, Lin JY.

Arch Dermatol. 2012 Mar;148(3):363-6. doi: 10.1001/archdermatol.2011.3080.

PMID:
22431777
49.

Interkingdom gene transfer of a hybrid NPS/PKS from bacteria to filamentous Ascomycota.

Lawrence DP, Kroken S, Pryor BM, Arnold AE.

PLoS One. 2011;6(11):e28231. doi: 10.1371/journal.pone.0028231. Epub 2011 Nov 29.

50.

Case records of the Massachusetts General Hospital. Case 30-2010. A 15-year-old boy with a recurrent skin lesion.

Tsao H, Tanabe KK, Lawrence DP, Piris A.

N Engl J Med. 2010 Sep 30;363(14):1352-60. doi: 10.1056/NEJMcpc1003889. No abstract available.

PMID:
20879885

Supplemental Content

Loading ...
Support Center